Galenix plans US expansion
raise the profile of its drug delivery technologies.
The company's chief executive, Jerome Besse, said in a statement that he expects to set up an East Coast office later this year, to help it find additional customers in North America.
Situated near the community of Saint-Jean d'Illac, near Bordeaux, Galenix has developed several new technologies for sustained release.
The first of these, Minextab (minimum excipient tablet), enables the production of tablets with at least 90 per cent active substance, and can be adapted to immediate, modified and slow release. A variant on the technology called Minextab Floating uses similarly small amounts of excipients and retains the active in the stomach.
The Mucolys line of sustained release films and powders for buccal applications includes a rapid acting version - Mucolys Flash - that releases active molecules in under five seconds on the tongue, and Mucolys Film for releasing molecules through the mucus membrane and thus reducing the effect of the first transit through the liver.
The company also offers a dry micro-emulsion technology called Microgix to improve the absorption of drugs with low solubility and low permeability, allowing for a broad range of absorption rates.
Aside from these technologies, Besse said that Galenix also offers a lean, efficient project management approach that shortens the time it takes to get a drug into the new delivery system and through development.
"What takes the big pharma companies three years to do, Galenix accomplishes in 18 months," he claimed.
